Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report

Human epidermal growth factor receptor 2 (HER2) mutation in non-small cell lung cancer (NSCLC) is an oncogenic driver that possibly becomes a druggable target to HER2-targeted therapy. The benefit of HER2-targeted therapy is much less defined especially in eastern populations. We provide evidence of...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Korean Med Sci
Main Authors: Park, Cheol Kyu, Hur, Jae Young, Choi, Chang-Min, Kim, Tae-Ok, Cho, Hyun-Ju, Shin, Hong-Joon, Lim, Jung-Hwan, Choi, Yoo-Duk, Kim, Young-Chul, Oh, In-Jae
Formato: Artigo
Idioma:Inglês
Publicado: The Korean Academy of Medical Sciences 2017
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5729642/
https://ncbi.nlm.nih.gov/pubmed/29215816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2018.33.e7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares